The prevalence of unsupervised hormone use among transgender people ranged between 29% and 63% in New York City and Ontario, and was associated with health risks, such as hypercoagulability and decreased insulin sensitivity [41, 42]. The gene discussed is INS; the disease is thrombophilia.